EACS 2015: Risk of Heart Attack Rises with Length of HIV Infection, Regardless of Age

alt

A decade after becoming infected, a person living with HIV has approximately twice the risk of heart attack compared to someone who has just acquired HIV, regardless of the age at which they seroconverted and after taking into account the effects of aging, according to an analysis of 18,468 people with HIV presented at the 15th European AIDS Conference in Barcelona last week. Stopping smoking, improving diet, and exercising are especially important for people living with HIV long-term, the researchers suggested.

[Produced in collaboration with Aidsmap.com]

The duration of HIV infection was one of the strongest predictors of heart attack, and it did not matter whether a person had a fully suppressed viral load or very high viral load. Severe immune suppression did raise the risk, however. Having a current CD4 cell count below 100 cells/mm3 was associated with an approximate 4-fold increase in risk compared with having a higher count.

The study was designed to determine which factors are most strongly linked with a raised risk of heart attack in people living with HIV, and specifically, how HIV infection might contribute to the risk.

Previous analyses of the D:A:D (Data Collection on Adverse Events of Anti-HIV Drugs) cohort, established in order to analyze the long-term effects of antiretroviral therapy, have suggested that several antiretroviral drugs are associated with an increased risk of heart attack, including abacavir (Ziagen, also in Epzicom or Kivexa), indinavir (Crixivan), and lopinavir/ritonavir (Kaletra).

The most recent report from the D:A:D cohort continued to show an association between the nucleoside analog abacavir and a raised risk of heart attack. A meta-analysis of 23 studies carried out before 2010 found that both HIV infection and exposure to antiretroviral therapy were associated with an increased risk of heart attack. This meta-analysis found that a greater duration of treatment with protease inhibitors, especially lopinavir/ritonavir, modestly increased the risk of heart attack, as did current abacavir use.

Although that meta-analysis found an association between HIV infection and a elevated risk of heart attack, it did not examine duration of infection, immune suppression, HIV viremia, or other factors that have been proposed as possible contributors to a raised risk of heart attack. All these factors might contribute to the burden of inflammation.

Uncontrolled HIV replication causes inflammation, and even when viral load is fully suppressed on treatment, some studies have found evidence of chronic low-level inflammation. Inflammatory chemicals seem to contribute to the process of atherosclerosis -- the hardening and narrowing of arteries -- that leads to a heart attack.

The analysis presented at the European AIDS Conference, by Alexandra Lyons from University College London, looked at the association between heart attack and the duration of HIV infection, latest CD4 count and HIV viral load, nadir (lowest-ever) CD4 count, duration of immune-suppression below a CD4 count of 200 cells/mm3, and prior AIDS diagnosis.

The study analyzed data from 8 cohorts comprising 18,468 people living with HIV in Europe and North America as part of the CASCADE collaboration in EuroCoord, a network which pools data on HIV in order to answer questions about patient outcomes. 80% of participants were male, with a median age of 32 years at the time of infection.

The 8 cohorts accumulated a total of 128,249 person-years (PY) of follow-up. During this follow-up period a total of 116 people had a heart attack.

An important limitation of this study is that owing to the quality of record keeping by physicians, it was not possible to distinguish between a first and subsequent heart attack. People who have had a first attack are at higher risk of another heart attack regardless of any other risk factors, and the inclusion of these cases may have biased the results somewhat.

After adjusting for the effects of age, exposure to indinavir or lopinavir/ritonavir, and current abacavir use, the analysis showed a substantial increase in the risk of heart attack for every 10-year greater duration of HIV infection.

The rate of heart attack increased with duration of infection, from 0.43 per 1000 person-years among people infected with HIV for 5 years or less, to 0.86 per 1000 person-years among those infected for 5 to 10 years, 1.06 per 1000 person-years among those infected for 10 to 15 years, and 2.65 per 1000 person years among those infected for more than 15 years.

To put these figures into everyday terms, in a clinic with 1000 patients who had all been living with HIV for at least 15 years, 2 to 3 patients could be expected to have a heart attack each year. This rate is in fact fairly low in comparison with some other studies of heart attack risk, and Lyons said that it was possible that heart attacks had been under-reported.

The analysis also found that people with current CD4 counts below 100 cells/mm3 had a much greater rate of heart attack (4.52 per 1000 person-years) compared to those with higher CD4 cell counts.

Multivariable analysis showed that after adjusting for age, antiretroviral drug exposure, and current and nadir CD4 cell count, each 10 years of HIV infection had a similar impact as 10 years of ageing on heart attack risk. In other words, a 40-year-old person with HIV infected with HIV for 10 years might have a similar risk of heart attack as a 50-year-old person without HIV.

Lyons concluded that guidelines for cardiovascular risk management for people living with HIV may need to consider duration of HIV infection as an independent risk factor, and that particular emphasis needs to be placed on addressing risk factors like diet, smoking, and exercise in people who have been infected with HIV for a long time, regardless of their age.

11/1/15

Reference

A Lyons, D Costagliola, C Mussini, et al. Is HIV Infection Duration Associated with Myocardial Infarctions? 15th European AIDS Conference. Barcelona, October 21-24, 2015. Abstract PS11/3.